Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy causing bone lesions, organ damage, and reduced survival.
• Historically considered incurable, MM outcomes have significantly improved over the last two decades.

Purpose of the Study:

• To review recent therapeutic advancements in multiple myeloma.
• To highlight novel agents targeting plasma cell proliferation and the tumor microenvironment.

Main Methods:

• Review of recent literature on multiple myeloma therapeutics.
• Categorization of novel agents by mechanism of action (immunomodulators, proteasome inhibitors, monoclonal antibodies, etc.).

Main Results:

• Development of immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide).
• Introduction of proteasome inhibitors (bortezomib, ixazomib, carfilzomib).
• Emergence of targeted therapies including monoclonal antibodies (elotuzumab, daratumumab), bispecific T-cell engagers (teclistamab), and CAR-T strategies.

Conclusions:

• Novel therapeutics have dramatically improved MM patient outcomes, including survival and quality of life.
• Current research focuses on targeted therapies with enhanced efficacy against neoplastic plasma cells and the tumor microenvironment.